Exagen Diagnostics (XGN): Earnings per share for the last twelve months

Official company branding of Exagen (XGN)

The 12-month net income per share trend for Exagen Inc. (XGN) reflects the impact of slow test adoption and liquidity costs. However, the uniqueness of AVISE diagnostics in early arthritis detection and the deep integration of software into rheumatology create a solid foundation. The current level is -0.75, which allows for a real-time assessment of the business's financial stability amid expensive borrowed capital.

XGN (exagen.com) Net earnings per one share for the last twelve months history from 07/04/2022 to 11/16/2026

Summary analytical data breakdowns for Exagen Diagnostics (XGN)

- stock price and consensus target price:
- stock exchange capitalization data:
Comprehensive company analysis:exagen.com (XGN)
Manufactured products of Exagen Inc

Exagen Inc. revenues depend directly on the scaling of diagnostic tests and their integration into insurance protocols. The 12-month trend in the company's per-share profit reflects the actual efficiency of this model, stripping net income of the impact of share issuance. It is critical for investors to track this indicator as an objective marker of business strategy execution, eliminating the subjectivity of corporate forecasts.

Main competitors

agilent.com - Net earnings per share (EPS TTM)|Net earnings per share for the last four quarters Quest Diagnostics Inc. DGX|ILMN: Net earnings per share (EPS TTM)|EXAS - Net earnings per share for the last four quarters|Earnings per share for the last twelve months revvity.com|Earnings per share for the last twelve months BIO|Net earnings per share (EPS TTM) NNNN|SHC - Net earnings per one share for the last twelve months|Quidel Corporation - Net earnings per share for the last 12 months|Net earnings per share (EPS TTM) OPKO Health Corp. OPK|CDNA - Earnings per share for the last twelve months|Earnings per share for the trailing year MRVI (Maravai LifeSciences)|FLGT: Net earnings per share (EPS TTM)|Earnings per share for the last 12 months LAB|Earnings per share for the last twelve months Cytek Biosciences Inc|Net earnings per share (EPS TTM) OraSure Corp|Net earnings per share (EPS TTM) MDXH|LUCD (Lucid Diagnostics Inc.) - Earnings per share for the trailing year|Net earnings per share (EPS TTM) PRE (Prenetics Global)|Earnings per share for the last four quarters IMDX (imdxinc.com)|TRIB: Net earnings per share for the last 12 months|Net earnings per one share for the last twelve months ProPhase Labs, Inc.|AIMD: Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months codiagnostics.com (CODX)|Net earnings per share for the last 12 months HSCS|BMRA: Earnings per share for the trailing year|Net earnings per share (EPS TTM) CDIO|Net earnings per share for the last four quarters Onconetix Corporation|Net earnings per share (EPS TTM) VRAX (Virax Biolabs Group)|Net earnings per share for the trailing year bluejaydx.com|AWH: Net earnings per share for the last 12 months|Net earnings per share for the last four quarters Accelerate Diagnostics, Inc. AXDX|CNTG (CENTOGENE) - Net earnings per share for the last 12 months|Earnings per share for the last 12 months ENZ|FRES: Net earnings per share for the last four quarters|Earnings per share for the last twelve months GENE|Net earnings per share for the last 12 months ME (23andMe Holding Co)|PMD - Net earnings per one share for the last twelve months